Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer

Genes Chromosomes and Cancer

Volumn 51, Issue 9, 2012, Pages 832-840

  Partanen, Laura ^a   Staaf, Johan ^b   Tanner, Minna ^c   Tuominen, Vilppu J ^a   Borg, Åke ^b   Isola, Jorma ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 3;

ABCC3 GENE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHROMOSOME 17Q; COMPUTER MODEL; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENE PROBE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 84863565481     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21967     Document Type: Article

References (25)

1. Borst P, Elferink RO. 2002. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592.
2. Borst P, Evers R, Kool M, Wijnholds J. 2000. A family of drug transporters: The multidrug resistance-associated proteins. J Matl Cancer Inst 92: 1295-1302.
3. Borst P, de Wolf C, van de Wetering K. 2007a. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch 453: 661-673.
4. Borst P, Jonkers J, Rottenberg S. 2007b. What makes tumors multidrug resistant? Cell Cycle 6: 2782-2787.
5. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. 2011. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29: 398-405.
6. Davoli A, Hocevar BA, Brown TL. 2010. Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol 65: 611-623.
7. Glynn RW, Miller N, Kerin MJ. 2010. 17q12-21-The pursuit of targeted therapy in breast cancer. Cancer Treat Rev 36: 224-229.
8. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. 2006. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
9. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JMS. 2004. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 10: 4793-4798.
10. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg Å, Grénman S, Isola J. 2000. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156: 839-847.
11. Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A. 2010. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 3: R42.
12. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P. 1999. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96: 6914-6919.
13. Lackner M, Amler LC, Cavet G, O'Brien C, Pandita A. 2011. Genetic variations associated with drug resistance. US Patent Application 20110177099, released July 21, 2011; accessed Oct 10, 2011 at www.uspto.gov.
14. Liu YH, Di YM, Zhou ZW, Mo SL, Zhou SF. 2009. Multidrug resistance associated proteins and implications in drug development. Clin Exp Pharmacol Physiol 37: 115-120.
15. O'Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, Toy K, Rivers CS, Modrusan Z, Amler LC, Lackner MR. 2008. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 68: 5380-5389.
16. O'Connor R. 2007. The pharmacology of cancer resistance. Anticancer Res 27: 1267-1272.
17. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. 2009. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
18. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. 2011. Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 29: 859-867.
19. Rasband WS. 1997-2011. ImageJ. U.S. National Institutes of Health, Bethesda, MD. Available at.
20. Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johansson OT, Loman N, Barkardottir RB, Borg Å. 2010. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 12: R25.
21. Staaf J, Jonsson G, Ringner M, Baldetorp B, Borg A. 2011. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 13: R129.
22. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. 2006. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
23. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. 2004. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3: 1585-1592.
24. Tuominen VJ, Isola J. 2009. The application of JPEG2000 in virtual microscopy. J Digit Imaging 22: 250-258.
25. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. 2001. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7: 1798-1804.